Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study.
Soichiro HozawaHiroyuki OhbayashiMichiko TsuchiyaYu HaraLaurie A LeeTakashi NakayamaJun TamaokiAndrew FowlerTakanobu NishiPublished in: Journal of asthma and allergy (2021)
In this uncontrolled open-label study, no new safety concerns were observed with long-term (52 weeks) treatment with once-daily FF/UMEC/VI among 111 Japanese patients with asthma.